CA3030163A1 - Recombinant polypeptides comprising selenocysteine and method for producing the same - Google Patents

Recombinant polypeptides comprising selenocysteine and method for producing the same Download PDF

Info

Publication number
CA3030163A1
CA3030163A1 CA3030163A CA3030163A CA3030163A1 CA 3030163 A1 CA3030163 A1 CA 3030163A1 CA 3030163 A CA3030163 A CA 3030163A CA 3030163 A CA3030163 A CA 3030163A CA 3030163 A1 CA3030163 A1 CA 3030163A1
Authority
CA
Canada
Prior art keywords
substitution
position corresponding
seq
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3030163A
Other languages
English (en)
French (fr)
Inventor
Andrew D. Ellington
Ross Thyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of CA3030163A1 publication Critical patent/CA3030163A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
CA3030163A 2016-07-11 2017-07-10 Recombinant polypeptides comprising selenocysteine and method for producing the same Pending CA3030163A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662360745P 2016-07-11 2016-07-11
US62/360,745 2016-07-11
PCT/US2017/041373 WO2018013481A1 (en) 2016-07-11 2017-07-10 Recombinant polypeptides comprising selenocysteine and method for producing the same

Publications (1)

Publication Number Publication Date
CA3030163A1 true CA3030163A1 (en) 2018-01-18

Family

ID=60953318

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3030163A Pending CA3030163A1 (en) 2016-07-11 2017-07-10 Recombinant polypeptides comprising selenocysteine and method for producing the same

Country Status (6)

Country Link
US (1) US11155804B2 (enExample)
EP (1) EP3481945A4 (enExample)
JP (2) JP7269648B2 (enExample)
CN (1) CN109844105A (enExample)
CA (1) CA3030163A1 (enExample)
WO (1) WO2018013481A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7186400B2 (ja) 2016-08-30 2022-12-09 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ゲノム的に再コードした生物におけるセレノ－生物製剤の製造
CN109486802B (zh) * 2018-12-26 2020-08-04 广州白云山拜迪生物医药有限公司 一种酶活提高的青霉素酶突变体及其构建方法
WO2025024577A1 (en) * 2023-07-24 2025-01-30 Board Of Regents, The University Of Texas System Incorporating unnatural amino acids using one pot pure system
CN120158472A (zh) * 2023-10-18 2025-06-17 河南农业大学 玉米ZmmtRF2a基因及其克隆引物在调控籽粒发育中的应用
CN121627877B (zh) * 2025-12-26 2026-08-07 吉林农业大学 一种抗鹿源牛病毒性腹泻病毒e2蛋白的重组单克隆抗体及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10309193A (ja) 1997-05-12 1998-11-24 Sankyo Co Ltd 哺乳類セレノシステイン含有タンパク質の大腸菌での製造法
US6849417B1 (en) 1998-04-06 2005-02-01 The United States Of America As Represented By The Department Of Health And Human Services Mammalian selenoprotein differentially expressed in tumor cells
WO2001012657A2 (en) * 1999-08-16 2001-02-22 Karolinska Innovations Ab Methods and means for selenoprotein expression
EP1437410A4 (en) 2001-09-13 2005-01-26 Juridical Foundation NEW SELENOCYSTEIN CONTAINING PROTEINS
WO2007075438A2 (en) 2005-12-15 2007-07-05 Codon Devices, Inc. Polypeptides comprising unnatural amino acids, methods for their production and uses therefor
WO2008140477A2 (en) 2006-11-02 2008-11-20 Capon Daniel J Hybrid immunoglobulins with moving parts
WO2009043051A2 (en) 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
CA2703830A1 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
RU2013139260A (ru) 2011-01-28 2015-03-10 Нэшнл Рисеч Каунсил Оф Канада Конструирование иммуноглобулиновых доменов
CA2838833A1 (en) * 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
US10876142B2 (en) 2011-07-11 2020-12-29 Yale University Compositions and methods for making selenocysteine containing polypeptides
WO2013009868A1 (en) 2011-07-11 2013-01-17 Yale University Compositions and methods for making selenocysteine containing polypeptides
US10240158B2 (en) 2011-07-11 2019-03-26 Yale University Compositions and methods for making selenocysteine containing polypeptides
US20160017058A1 (en) 2013-03-14 2016-01-21 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
US20150050682A1 (en) 2013-08-15 2015-02-19 University Of Vermont And State Agricultural College Direct assay of thioredoxin reductase activity
WO2015066543A1 (en) 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
US10118950B2 (en) * 2014-08-30 2018-11-06 Northwestern University Platforms for cell-free protein synthesis comprising extracts from genomically recoded E. coli strains having genetic knock-out mutations in release factor 1 (RF-1) and endA
WO2016172269A2 (en) 2015-04-20 2016-10-27 University Of Utah Research Foundation Insulin analogs having shortened b chain peptides and associated methods
US10557160B2 (en) 2015-12-15 2020-02-11 Board Of Regents, The University Of Texas System Transgenic bacteria with expanded amino acid usage and nucleic acid molecules for use in the same
WO2018014091A1 (en) 2016-07-22 2018-01-25 University Of Utah Research Foundation Insulin analogs
JP7186400B2 (ja) 2016-08-30 2022-12-09 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ゲノム的に再コードした生物におけるセレノ－生物製剤の製造

Also Published As

Publication number Publication date
JP2023060001A (ja) 2023-04-27
CN109844105A (zh) 2019-06-04
JP2019520083A (ja) 2019-07-18
US20190316110A1 (en) 2019-10-17
EP3481945A4 (en) 2020-07-29
WO2018013481A1 (en) 2018-01-18
US11155804B2 (en) 2021-10-26
JP7269648B2 (ja) 2023-05-09
EP3481945A1 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
JP2023060001A (ja) セレノシステインを含む組換えポリペプチド及びその製造方法
JP6932693B2 (ja) カッパ及びラムダ軽鎖を含む抗原結合ポリペプチド構築物及びその使用
KR102168733B1 (ko) 중쇄와 경쇄의 회합이 제어된 항원 결합 분자
KR101856792B1 (ko) 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법
US12516106B2 (en) Method for protein purification
CN116041516A (zh) 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
US20230303694A1 (en) Antibodies that bind gamma-delta t cell receptors
CN103429737A (zh) 细胞毒诱导治疗剂
US20230121511A1 (en) Method for producing multispecific antigen-binding molecules
CN119630697A (zh) Ph依赖性hsa结合分子及使用方法
EP3155013B1 (en) Method for selecting antibodies with modified fcrn interaction
TW202535947A (zh) ＣＤ３３抗體、ＣＤ３３／Ｖδ２多特異性抗體及其用途
US12428496B2 (en) Antibodies, compositions for use in detecting or capturing a polypeptide in a sample, and methods for detecting or capturing a polypeptide in a sample
WO2018199214A1 (ja) 薬物動態が改善された血液凝固第ｉｘ因子
HK40008291A (en) Recombinant polypeptides comprising selenocysteine and method for producing the same
CN115956124A (zh) 改善蛋白质表达的方法
US20250109204A1 (en) Compositions comprising antibodies that bind gamma-delta t cell receptors
JP2022060048A (ja) 抗体及びその使用
RU2779602C2 (ru) Устойчивые мультиспецифические антитела
CN120424216A (zh) 一种抗cd123抗体及其用途
WO2025086263A1 (zh) 抗Taq DNA聚合酶单克隆抗体及其应用
CN117999286A (zh) 用于治疗癌症的CD33 x Vδ2多特异性抗体
HK1188254B (en) Cytotoxicity-inducing therapeutic agent
HK1188254A (en) Cytotoxicity-inducing therapeutic agent

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220425

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240924

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250129

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250519

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250519

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250624

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250624

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251222

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260421

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260427

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260427

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260427